Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting (GlobeNewswire) - Jun 13, 2022 - "The Company expects to initiate a Phase 2/registrational trial of 186RNL in patients with recurrent GBM by the end of 2022. In addition, the Company is continuing to evaluate 186RNL in leptomeningeal metastases as part of the ReSPECT-LM Phase 1/2a dose escalation clinical trial and is in late-stage planning for the treatment of pediatric ependymoma and high-grade GBM....Additionally, Russ Havranek, Vice President of Corporate Strategy and New Product Planning of Plus Therapeutics will present a corporate update in person at the BIO International Convention 2022 on June 15 at 10:30 AM PT in San Diego, California."
New P2 trial • Trial status • CNS Tumor • Ependymoma • Glioblastoma • Oncology
|